RLAY Stock Analysis: Relay Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 4.172m USD | 12M Return: 358% | US75943R1023 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 50.3M
Qual. Beats: 0
Rev. Trend: -68.7%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Relay Therapeutics is a clinical-stage precision medicines company that leverages computational analysis of protein motion to discover small molecule therapeutics, with a primary focus on targeted oncology and genetic diseases. Its drug discovery platform is built around long collaboration with D. E. Shaw Research, whose high-performance computing capabilities model protein dynamics to inform compound design. The company is headquartered in Cambridge, Massachusetts, was incorporated in 2015, and completed its IPO on NASDAQ in July 2020.
The companys lead clinical programs include RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor being developed for breast cancer, solid tumors, and vascular malformations; lirafugratinib (RLY-4008), a receptor tyrosine kinase inhibitor for cancer; RLY-8161, an oncogene driver candidate targeting the RAS family; and an alpha-Galactosidase A (aGal) chaperone for Fabry disease. RLAY-2608 is being advanced in combination with fulvestrant and atirmociclib under a collaboration with Pfizer, while RLY-4008 is being developed and commercialized in partnership with Elevar Therapeutics.
Operating within the GICS Biotechnology sub-industry, Relay Therapeutics fits the typical clinical-stage biotech profile: it has no approved products on the market and its valuation is primarily driven by pipeline progress and partnership milestones rather than recurring revenue. Mid-cap status and a recent IPO reflect a company still pre-commercial, with cash runway and clinical readouts serving as the key near-term catalysts for shareholders.
- RLY-2608 breast cancer data readout remains primary stock catalyst
- Cash burn from clinical-stage operations risks future equity dilution
- Pfizer partnership validates RLY-2608 combination development strategy
| Net Income: -286.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 14.02 > 1.0 |
| NWC/Revenue: 8.48k% < 20% (prev 7.75k%; Δ 722.8% < -1%) |
| CFO/TA -0.22 > 3% & CFO -212.2m > Net Income -286.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 18.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (202.8m) vs 12m ago 18.44% < -2% |
| Gross Margin: 65.63% > 18% (prev -3.68k%; Δ 3.74k% > 0.5%) |
| Asset Turnover: 1.22% > 50% (prev 1.15%; Δ 0.07% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.91 (Total Current Assets 928.1m - Total Current Liabilities 50.8m) / Total Assets 967.5m |
| B: -2.24 (Retained Earnings -2.17b / Total Assets 967.5m) |
| C: -0.34 (EBIT TTM -286.0m / Avg Total Assets 848.1m) |
| D: 11.49 (Book Value of Equity 890.0m / Total Liabilities 77.4m) |
| Altman-Z'' = 8.43 = AAA |
As of September 17, 2026, the stock is trading at USD 18.87 with a total of 4,164,326 shares traded. Over the past week, the price has changed by -0.74%, over one month by -5.60%, over three months by +32.51% and over the past year by +358.01%.
Current recommended Stop Loss: 17.20 (which is 8.9% or 1.8 ATR below the current price).
Relay Therapeutics has received a consensus analysts rating of 4.31. Therefore, it is recommended to buy RLAY.
- StrongBuy: 6
- Buy: 5
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 27.1 | 43.5% |
P/S = 403.1359
P/B = 4.5601
Revenue TTM = 10.3m USD
EBIT TTM = -286.0m USD
EBITDA TTM = -283.8m USD
Long Term Debt = 26.6m USD (estimated: total debt 30.7m - short term 4.01m)
Short Term Debt = 4.01m USD (from shortTermDebt, last quarter)
Debt = 30.7m USD (from shortLongTermDebtTotal, last quarter) (leases 30.7m already included)
Net Debt = -880.3m USD (calculated: Debt 30.7m - CCE 910.9m)
Enterprise Value = 3.29b USD (4.17b + Debt 30.7m - CCE 910.9m)
Interest Coverage Ratio = unknown (Ebit TTM -286.0m / Interest Expense TTM 0.0)
EV/FCF = -15.51x (Enterprise Value 3.29b / FCF TTM -212.2m)
FCF Yield = -6.45% (FCF TTM -212.2m / Enterprise Value 3.29b)
FCF Margin = -2.05k% (FCF TTM -212.2m / Revenue TTM 10.3m)
Net Margin = -2.76k% (Net Income TTM -286.0m / Revenue TTM 10.3m)
Gross Margin = 65.63% ((Revenue TTM 10.3m - Cost of Revenue TTM 3.56m) / Revenue TTM)
Gross Margin QoQ = none% (prev 83.20%)
Tobins Q-Ratio = 3.40 (Enterprise Value 3.29b / Total Assets 967.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 30.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -226.0m (EBIT -286.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 18.27 (Total Current Assets 928.1m / Total Current Liabilities 50.8m)
Debt / Equity = 0.03 (Debt 30.7m / totalStockholderEquity, last quarter 890.0m)
Debt / EBITDA = 3.10 (negative EBITDA) (Net Debt -880.3m / EBITDA -283.8m)
Debt / FCF = 4.15 (negative FCF - burning cash) (Net Debt -880.3m / FCF TTM -212.2m)
Total Stockholder Equity = 676.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.72% (Net Income -286.0m / Total Assets 967.5m)
RoE = -42.27% (Net Income TTM -286.0m / Total Stockholder Equity 676.7m)
RoCE = -40.67% (EBIT -286.0m / Capital Employed (Equity 676.7m + L.T.Debt 26.6m))
RoIC = -24.56% (negative operating profit) (NOPAT -226.0m / Invested Capital 920.1m)
WACC = 12.03% (E(4.17b)/V(4.20b) * Re(12.12%) + D(30.7m)/V(4.20b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.12% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.28 | Cagr: 21.52%
[DCF] Fair Price = unknown (Cash Flow -212.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -68.70 | Revenue CAGR: -35.84% | SUE: -0.12 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.40 | Chg30d=-3.68% | Revisions=-10% | Analysts=12
EPS current Year (2026-12-31): EPS=-1.62 | Chg30d=-5.86% | Revisions=-58% | GrowthEPS=-0.4% | GrowthRev=-31.4%
EPS next Year (2027-12-31): EPS=-1.64 | Chg30d=+0.21% | Revisions=+25% | GrowthEPS=-1.3% | GrowthRev=+57.2%
[Analyst] Revisions Ratio: -35% (up=5, down=12)